Management of portopulmonary hypertension: New perspectives

Luigi Mancuso, Francesca Scordato, Michela Pieri, Eliana Valerio, Andrea Mancuso

Abstract

Portopulmonary hypertension (PPHTN) is a known complication of cirrhosis. Moderate-to-severe PPHTN implies an extremely poor prognosis. It occurs in 5%-10% of patients referred for liver transplantation (LT), and probably with an higher incidence in patients with large portosystemic shunts. Patients with moderate-to-severe pulmonary hypertension have been previously excluded from LT because of the extremely high surgical risk and since the post-transplant outcome reported was poor. Recently, new perspectives in the management of patients with portopulmonary hypertension are emerging. In fact, some pulmonary vasoactive drugs have become routine in the treatment of patients with idiopathic pulmonary hypertension. These drugs, particularly epoprostenol, have been recently introduced in the treatment of patients with PPHTN, and have been shown to be effective in reducing pulmonary artery pressure as well as pulmonary vascular resistances. Furthermore, recent studies seem to demonstrate that treatment with pulmonary vasoactive drugs could allow liver transplantation with acceptable surgical risks and excellent survival. Although there are not large series nor prospective studies addressing this topic, the clinical scenario of patients with PPHTN seems to be positively changing.
the majority of patients succumbing within 2 years.\textsuperscript{[1-4]}

PPHTN affects 1%-2% of patients with portal hypertension or cirrhosis and 5%-10% of patients being evaluated for liver transplantation.\textsuperscript{[5]}

Diagnosis is suggested by either elevation of the right ventricular systolic pressure or right ventricular dysfunction on echocardiography, but requires confirmation by right heart catheterization.\textsuperscript{[6-8]}

**DEFINITION OF PORTOPULMONARY HYPTERTENSION**

PPHTN definition has evolved over time, specifically with regard to the cutoff for pulmonary vascular resistances (PVR). Initial studies used PVR > 120 dynes s cm\(^{-5}\) as abnormal. Subsequent studies and the Consensus Report of the European Respiratory Task Force on pulmonary vascular diseases associated with liver diseases have recommended PVR > 240 dynes s cm\(^{-5}\) as the “gold standard”.

Therefore the current consensus diagnostic criteria for PPHTN include mean pulmonary artery pressure (MPAP) > 25 mmHg, PVR > 240 dynes s cm\(^{-5}\), and pulmonary artery occlusion pressure (PAOP) < 15 mmHg.\textsuperscript{[1,6,7]}

Since it has been shown that some patients with PAOP > 15 mmHg and PVR > 240 dynes s cm\(^{-5}\) may present a trans-pulmonary gradient (TPG) strongly suggestive of obstruction to pulmonary arterial flow, recently new criteria have been proposed by authors from Mayo Clinic.\textsuperscript{[8]}

In fact, many patients managed as pulmonary hypertension have elevated left-sided filling pressure, probably due to ventricular interaction. Then, it has been recently proposed that only values of PAOP higher than 18 mmHg exclude the diagnosis of PPHTN.\textsuperscript{[9-12]}

**PATHOPHYSIOLOGY AND PATHOGENESIS**

PPHTN involves endothelial and smooth muscle proliferation, and have the same features of plexogenic arteriopathy of Idiopathic Pulmonary Hypertension (Figure 1). There is not a clear link between portal hypertension and the development of PPHTN. Because only 5%-10% of patients with portal hypertension develop PPHTN, factors other than portal hypertension must be involved in its development. Moreover, the link between liver dysfunction and PPHTN is not obvious, because PPHTN may develop in cases of portal vein thrombosis or idiopathic hypertension, in absence of any liver dysfunction. Data of a recent retrospective study by Talwalkar et al, suggest a strong association between large portosystemic shunts, hepatofugal portal blood flow, and PPHTN. These data may support the hypothesis that vasoactive factors from the splanchnic circulation may be pathogenic for PPHTN development. The fact that the most occurring shunt observed in this study was splenorenal might suggest that the blood flow coming from the spleen, which is involved in the destruction of platelets and prostaglandins delivery, might be of primary importance in the PPHTN pathogenesis. Moreover, presence of large portosystemic shunts, such as those reported in this study; seems to be associated with lack of response to vasoactive treatment.
PROGNOSIS OF PPHTN AND LIVER TRANSPLANTATION

Moderate-to-severe PPHTN (MPAP ≥ 35 mmHg) that is present in up to 5%-10% of patients referred for liver transplantation (LT) [16,17], excludes patients from LT in most of the centers, since post-transplant outcome is poor and because of the high surgical risk [11-13].

A multicenter transplant database has shown that 36% of PPHTN patients died during the immediate post-transparent period due to progressive right ventricular failure, acute respiratory distress syndrome and cardiovascular collapse [11]. Moreover, Krowka et al. [14] reported that only 29% of transplanted patients with untreated PPHTN survived 3 years.

VASODILATION TREATMENT IN PPHTN

Several vasomodulating and vasodilating drugs have been introduced for the treatment of idiopathic pulmonary hypertension. More recently, vasomodulating and vasodilating drugs, available for the treatment of idiopathic pulmonary hypertension, have also been shown to significantly improve pulmonary hemodynamics in some patients with PPHTN [18-21].

Current medications target three pulmonary hypertension pathways. The first agent, the endothelin receptor antagonists, target the vasoconstrictive endothelin pathway. The second agent targets the prostacyclin pathway, resulting in vasodilation, antiplatelet effect, and vascular remodelling. The third one involves nitric oxide-mediated vasodilation through cyclic guanosine monophosphatase and the inhibition of the phosphodiesterase type 5 enzyme. Therefore, some drugs have a vasodilation effect, while others have remodeling and antiplatelet effects.

Since we do not yet know which is the predominant mechanism which determines pulmonary hypertension in patients with portal hypertension [4], different drugs have been used in the treatment of patients with PPHTN.

The drugs that have been mostly used for the treatment of patients with PPHTN are the prostacyclin analogues, such as Epoprostenol, inhaled Iloprost and Treprostinil. Epoprostenol is a potent pulmonary and systemic vasodilator, that also reduces platelet aggregation [16-18]. In PPHTN it has been shown to improve hemodynamics acutely, because of its vasodilator effects [19]. Furthermore, in two studies prolonged use of the drug has shown additional improvement [20,21]. A recent paper by Awdish et al. [20] reports the long-term effects of treatment with and without epoprostenol on pulmonary hemodynamics, liver function and survival, in a large retrospective cohort of patients with moderate to severe PPHTN. They showed significant improvements in mean pulmonary artery pressure, pulmonary vascular resistances and cardiac output with epoprostenol after a median of 15.4 mo, and no significant change of liver biochemistry. However, survival seemed not to differ between treatment groups. These studies argue against the hypothesis by Krowka that epoprostenol might worsen portal hypertension by increasing splenic blood flow and portal system congestion [20]. In fact, it is possible to hypothesize that by improving pulmonary hemodynamics and right heart function, epoprostenol could potentially improve liver function [21].

A recent prospective observation study has stressed the utility of early initiation of parenteral prostacyclin therapy in PPHTN patients, so improving 5-year survival, as compared with data of the REVEAL Registry [22].

There are scarce studies concerning the treatment with Treprostinil [23], and inhaled Iloprost [24], sometimes used together with other vasoactive drugs [25,26] in patients with PPHTN.

Concerning the endothelin receptor antagonists, such as Bosentan, there are some recent studies that seem to demonstrate a possible hemodynamic improvement and safety of these drugs [27-29]. Moreover, Bosentan has been administered together with different drugs in some studies: inhaled Iloprost [25,26,29], or with Sildenafil and Iloprost [24].

Phosphodiesterase inhibitor Sildenafil has the advantage of being an oral compound with pulmonary vasodilating action but no hepatotoxicity [30]. Few recent retrospective studies, performed in a small number of patients with PPHTN [10,13], seem to show that sildenafil might be effective in monotherapy, and in combination with inhaled prostanooids, leading to hemodynamic improvement. These data have also been confirmed by a recent paper by Krowka [14] reporting favorable follow up in seven patients with moderate or severe PPHTN treated with oral combination therapy.

LIVER TRANSPLANTATION FOLLOWING MEDICAL MANAGEMENT

PPHTN survival in the absence of transplantation has been reported in 38% at 3 years [1] and 28% at 5 years [15]. Furthermore, it has been demonstrated that PPHTN prognosis is worse than that of idiopathic pulmonary hypertension [1].

PPHTN is a serious problem in the context of liver transplantation. Mild PPHTN (MPAP < 35 mmHg) has scarce perioperative risks [31,32], but moderate disease (MPAP 35-45 mmHg, PVR > 250 dyne·s–cm–5) has been associated with a perioperative mortality of 50%-80% [8,38], and a MPAP > 50 mmHg is universally fatal [8,36,37].

Recently numerous studies have demonstrated the possibility of reducing MPAP and PVR, at least in some patients affected by PPHTN, leading to a decrease of perioperative risk due to liver transplantation. Moreover, some studies have shown that PPHTN may resolve following transplantation, presumably by removing the root cause of the problem [39-41].

As a consequence of recent improved knowledge of PPHTN management, a potential therapeutic opportunity arises: PPHTN might initially be controlled with vasodilator therapy and subsequently cured with liver transplantation. Several studies have been performed to examine the feasibility of this hypothesis [39-42]. Moreover,
in the last years some retrospective studies have been published reporting patients with PPHTN in whom liver transplantation was successfully performed after treatment with pulmonary vasoactive drugs. In the study by Ashfaq et al., 16 of 20 patients with moderate-to-severe pulmonary hypertension (MPAP ≥ 35 mmHg) were otherwise considered suitable liver transplant candidates and were treated with vasoactive pulmonary drugs (epoprostenol in 13, bosentan + epoprostenol in 1, sequential; bosentan + diltiazem + epoprostenol, sequential in 1, diltiazem in 1). In these patients MPAP fell to less than 35 mmHg in 12 (75%), and 11 of them underwent liver transplantation. One-year survival was 91%, and 5-year survival was 67%. Nine of 11 patients were off vaso dilator therapy after a median of 9.2 mo after transplantation. In patients who failed vaso dilator therapy median survival was 8 mo. The Authors conclude that effective pharmacologic control of PPHTN before transplantation is associated with posttransplant survival that is similar to patients transplanted for other indications.

In the study by Sussman et al., 8 cirrhotic patients with MPAP ≥ 35 mmHg, were treated with continuous intravenous epoprostenol (2-8 ng/kg per minute). In these patients liver transplant was considered if MPAP was lowered to < 35 mmHg. In seven patients the treatment improved hemodynamics within 6.5 mo therapy: mean vascular resistances declined from 410 to 192 dyne s cm-5, and cardiac output increased from 6.6 to 10 L/min. Six of the seven responders were listed for transplantation; two died on the waiting list; four were transplanted and remained alive and well after 9 to 18 mo post LT. Epoprostenol was continued throughout surgery and into the posttransplant period. In two of the patients it was possible to stop the vaso dilator therapy, whereas in two patients oral medication with bosentan was continued.

In the study by Swanson et al., a retrospective screening-right heart catheterization-survival analysis of patients with PPHTN was performed. Patients were categorized in three subgroups: (1) no vasoactive therapy and no transplantation; (2) therapy for pulmonary hypertension alone; and (3) therapy for pulmonary hypertension followed by liver transplantation. Even though it is a relatively small study, it seems to demonstrate that the survival of untreated patients was poor, whereas subgroups of patients selected to medical treatment with or without liver transplantation had better long-term survival. The best survival was in the subgroup of patients in whom liver transplantation was performed after effective medical therapy for pulmonary hypertension. However, it is to stress that this study is retrospective and reports a small number of patients. Moreover, 4 of 5 deaths in the LT group occurred in patients with PAOP ≤ 10 mmHg, while only two out of seven LT survivors had PAOP ≤ 10 mmHg. The authors hypothesize that lower values of PAOP may be correlated to lower cardiac outputs, and this might contribute to the poor prognosis. In the assessment of patients with PPHTN that are candidate to liver transplantation it is very important to perform an accurate evaluation of right ventricular function, because the success of undertaking liver transplantation will be determined by the ability of the right ventricle to sustain the increase of cardiac output and of pulmonary vascular resistance that acutely occur at the time of reperfusion that may cause acute right heart failure. Therefore, pre-transplant evaluation of right ventricular function by means of right heart catheterization and stress echocardiography is essential. Continuous intraoperative transoesophageal echocardiography has also been recommended for following right ventricular function.

MODEL FOR END-STAGE LIVER DISEASE AND PPHTN

Results of recent studies concerning LT following medical treatment in patients with PPHTN, as discussed above, probably change the clinical scenarios of patients with moderate or even severe pulmonary hypertension and portal hypertension.

Outcome of these patients, traditionally excluded from LT, could benefit from LT if a response to vasoactive therapy is evident. In fact, there is increasing evidence that many patients with PPHTN have important decrease of MPAP and PVR after therapy, so that they have excellent survival following liver transplantation. Furthermore, in some of these patients, vasoactive therapy may be stopped a few months after LT. Moreover, there is not any doubt that many patients who positively respond to medical therapy die on the waiting list for transplantation. Finally, another reason could supports early transplant of these patients. In fact, long-term intravenous epoprostenol, probably the most effective drug, is expensive, labor-intensive, requires hospitalization and is difficult to tolerate. These are the reasons why in some studies patients with PPHTN on intravenous therapy are given a MELD exception of 25 points in Region 4.

In a recent paper, Krowka et al. discuss this topic suggesting MELD exception (Meld score= 26 points) when the acceptable candidates satisfy the following criteria: (1) POPH exists with severity characterized by MPAP > 35 mmHg; and (2) a minimum of 12 wk of United States Food and Drug Administration-approved pulmonary arterial hypertension therapy results in the following hemodynamic profile: (1) MPAP < 35 mmHg and PVR < 400 dynes cm-5; and (2) satisfactory right ventricular function exists.

LIVER AND LUNG TRANSPLANTATION

Combined lung and liver transplantation is a therapeutic option for selected patients with coexisting lung and liver diseases such as cystic fibrosis and alfa 1 -proteinase inhibitor deficiency, and has also been performed in few cases of patients with PPHTN. Recently, a report concerning 13 consecutive patients who underwent combined lung and liver transplantation has been published. In the whole cohort of patients, 5 with PPHTN and 8 with other severe hepatic and pulmonary diseases (sarcoidosis, cystic
REFERENCES

1. Kawut SM, Taichman DB, Abhay VN, Kaplan S, Archer-Chicko CL, Kimmel SE, Palevsky H. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl 2005; 11: 1107-1111 [PMID: 16123953 DOI: 10.1002/hep.20459]

2. Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol 1991; 17: 492-498 [PMID: 1991908 DOI: 10.1016/s0735-1097(00)80124-1]

3. Herve P, Lebrec D, Borent F, Simonneau G, Humbert M, Sitbon O, Duroux P. Pulmonary vascular disorders in portal hypertension. Eur Respir J 1998; 11: 1133-1166 [PMID: 9648972 DOI: 10.1164/00007890-1999-11051153]

4. Swanson KB, Niewoehner DE, Nyberg SL, Rosen CB, Krowka MJ. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant 2008; 8: 2445-2453 [PMID: 18782292 DOI: 10.1111/j.1600-6143.2008.02384.x]

5. Kuo PC, Plotkin JS, Gaine S, Schroader RA, Rustgi VK, Rubin LJ, Johnson LB. Portopulmonary hypertension and the liver transplant candidate. Transplantation 1999; 67: 1087-1091 [PMID: 1023256 DOI: 10.1097/00007890-199904200-00001]

6. Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A, Mal H, Bernau J, Marty J, Lebrec D, Valla D, Durand F. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology 2003; 37: 401-409 [PMID: 12540791 DOI: 10.1053/jhep.2003.5006]

7. Benjamin FS, Prentice M, Sniderman KW, Siau S, Liu P, Wong F. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut 2003; 52: 1355-1362 [PMID: 12912870 DOI: 10.1136/gut.52.9.1355]

8. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Niewoehner DE, Krowka MJ, Andrews JC, Kaplan S. Evaluation of the surgical approach in the management of patients with PPHTN. Eur J Med 1996; 33: 288-301 [PMID: 8532025 DOI: 10.1054/nejm1996013340504]

9. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapsen VF, Bourge RH, Brundage BH, Koerner SK, Langleben D, Keller CA, Muriali S, Uretsky BF, Clayton LM, Jobms MS, Blackburn SD, Shortino D, Crow JW; Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1999; 341: 1107-1111 [PMID: 10250193 DOI: 10.1056/NEJM199904083410504]

10. Kawut SM, Frantz RP, McGoone MD, Severson C, Plevak DJ, Wiesner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999; 30: 641-648 [PMID: 10462369 DOI: 10.1021/he.0103003]

11. Halman M, Miehlke S, Hoeckfen G, Schmeisser A, Schulze M, Strasser RH. Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension. Transplantation 2004; 77: 1775-1776 [PMID: 15201684 DOI: 10.1097/01.TP.0000124240.36904.89]

12. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapsen VF, Bourge RH, Brundage BH, Koerner SK, Langleben D, Keller CA, Muriali S, Uretsky BF, Clayton LM, Jobms MS, Blackburn SD, Shortino D, Crow JW; Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1999; 341: 1107-1111 [PMID: 10250193 DOI: 10.1056/NEJM199904083410504]
Portopulmonary hypertension and right heart failure in patients with cirrhosis. Curr Opin Anaesthesiol 2010; 23: 145-150 [PMID: 20124995 DOI: 10.1097/ACO.0b013e3283372524]

Krowka MJ, Fallon MB, Mulligan DC, Gish RG. Model for end-stage liver disease (MELD) exception for portopulmonary hypertension. Liver Transpl 2006; 12: S114-S116 [PMID: 17123285 DOI: 10.1002/lt.20975]

Coujel PF, Houssin DP, Soubrane O, Chevalier PG, Dousset BE, Loulimet D, Achkar A, Tonel M, Amrein CI, Guinvarch A. Combined lung and liver transplantation in patients with cystic fibrosis. A 4 1/2-year experience. J Thorac Cardiovasc Surg 1995; 110: 1415-1422; discussion 1422-1223 [PMID: 74715193 DOI: 10.1016/S0022-5223(95)70064-1]

Coujel PF, Soubrane O, Houssin DP, Dousset BE, Chevalier PG, Guinvarch A, Loulimet D, Achkar A, Carpenter AF. Combined heart-lung-liver, double lung-liver, and isolated liver transplantation for cystic fibrosis in children. Transpl Int 1997; 10: 33-39 [PMID: 9002149 DOI: 10.1016/S0934-179X(97)00053-3]

Dennis CM, McNeil KD, Dunning J, Stewart S, Friend PJ, Alxander G, Higembottom AW, Calne RY, Wallwork J. Heart-lung-liver transplantation. J Heart Lung Transplant 1996; 15: 536-538 [PMID: 8771510]

Praseedom RK, McNeil KD, Watson CJ, Alexander GJ, Calne RY, Wallwork J, Friend PJ. Combined transplantation of the heart, lung, and liver. Lancet 2001; 358: 812-813 [PMID: 11564492 DOI: 10.1016/S0140-6736(01)05920-X, 3767370664]

Bashres NR, DiBardino DJ, McKenzie ED, Lee TC, Stayer SA, Mallory GB, Karpen SJ, Quiros-Tejera RE, Carter BA, Fraser CD, Goss JA. Combined lung and liver transplantation: the United States experience. Transplantation 2005; 80: 1161-1167 [PMID: 16314780 DOI: 10.1097/01.tp.00001577621362.09]

Trulock EP, Edwards LB, Taylor DO, Boucek MM, Keck BM, Hertz MI. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult lung and heart-lung transplant report—2005. J Heart Lung Transplant 2005; 24: 956-967 [PMID: 16102428 DOI: 10.1016/j.healun.2005.05.019]

Graznas G, Neipp M, Hoeper MM, Gottlieb J, Lück R, Becker T, Simon A, Strassburg CP, Manns MP, Welle T, Haverich A, Klemplnauer J, Nashan B, Strube M. Indications for and outcomes after combined lung and liver transplantation: a single-center experience on 13 consecutive cases. Transplantation 2008; 85: 524-531 [PMID: 18347530 DOI: 10.1097/TP.0b013e31816363f1]
